Ignite Creation Date:
2024-05-06 @ 3:20 PM
Last Modification Date:
2024-10-26 @ 1:48 PM
Study NCT ID:
NCT04603872
Status:
RECRUITING
Last Update Posted:
2020-10-28
First Post:
2020-10-21
Brief Title:
CAR-T Cells Combined With Dasatinib for Patients With Relapsed andor Refractory B-cell Hematological Malignancies
Sponsor:
Zhejiang University
Organization:
Zhejiang University
Study Overview
Official Title:
Clinical Trial for the Safety and Efficacy of CD19BCMA-targeted CAR-T Cells Combined With Dasatinib for Patients With Relapsed andor Refractory B-cell Acute Lymphoblastic Leukemia B-cell Non-Hodgkins Lymphoma and Multiple Myeloma
Status:
RECRUITING
Status Verified Date:
2020-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A Study of CD19BCMA-targeted CAR-T Cells Combined With Dasatinib for Patients With Relapsed andor Refractory B-cell Acute Lymphoblastic Leukemia B-cell Non-Hodgkins Lymphoma and Multiple Myeloma
Detailed Description:
This is a double-arm single-center study This study is indicated for relapsed andor refractory B-cell acute lymphoblastic leukemia B-cell non-Hodgkins lymphoma and multiple myeloma the selections of dose levels and the number of subjects are based on clinical trials of similar foreign products 120 patients will be enrolled for this trial Primary objective is to explore the safety
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None